Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 29,200 shares at $157.67 ($4.6M) on 2018-08-13, disclosed to the SEC on 2018-08-15.
Open-market sale of $4.6M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $157.67 | 1,600 | $252K | 5.4% |
| 2 | $157.67 | 1,600 | $252K | 5.4% |
| 3 | $158.51 | 4,233 | $671K | 14.4% |
| 4 | $158.51 | 4,233 | $671K | 14.4% |
| 5 | $159.63 | 3,367 | $537K | 11.6% |
| 6 | $159.63 | 3,367 |
| $537K |
| 11.6% |
| 7 | $160.49 | 800 | $128K | 2.8% |
| 8 | $159.13 | 1,600 | $255K | 5.5% |
| 9 | $159.93 | 7,100 | $1.1M | 24.4% |
| 10 | $160.75 | 1,300 | $209K | 4.5% |
| Total | $159.21 avg | 29,200 | $4.6M | 100% |
| Filing → |
| LOXO | SELL | 2018-11-28 | $2.9M | — | Filing → |
| LOXO | SELL | 2018-10-05 | $5.4M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $5.0M | — | Filing → |